Sarah Dias: Had an Honor of Presenting My Research at Cedars-Sinai Research Week 2026
Sarah Dias, Research Intern at Cedars Sinai, shared on LinkedIn:
”I had the incredible honor of presenting my research at Cedars-Sinai Research Week 2026!
For the past four months, I’ve been working as a Research Intern at the SkRIPT Stroke Lab, and I never could have imagined I would be presenting a research poster this fast.
Our study focused on MeVO AIS patients, those who experienced an acute ischemic stroke (AIS) secondary to a blockage of a medium-sized intracranial artery.
Our research aimed to determine which patient-specific characteristics can help predict who will actually benefit from endovascular thrombectomy, a minimally invasive procedure to remove the clot. While it’s standard care for larger strokes, its benefit for MeVO patients is still unproven.
We studied the Fazekas score, a measure of white matter disease in the brain, alongside clinical factors like limited pre-stroke disability.
In shift ordinal analysis of our full cohort, which compares outcomes across the entire disability scale (mRS 0–6), we found that greater white matter disease trended toward worse outcomes (higher mRS), though the association wasn’t statistically significant.
The interesting part came when we narrowed to patients matching the DISTALS trial criteria (higher stroke severity, limited pre-stroke disability).
There, the trend became significant: each 1-point increase in Fazekas score was associated with 66% higher odds of a worse functional outcome.
The takeaway: pairing more selective patient criteria with imaging biomarkers like Fazekas can meaningfully improve our ability to predict who benefits from thrombectomy in real-world MeVO patients.
It was such an honor to share my research with the greater Cedars community, and I am incredibly grateful to all my co-authors, especially my PI, Dr. Simpkins, for her support and for granting me this amazing opportunity.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?